Patient-Reported Outcomes for Neuroendocrine Tumors

(NET-PRO Trial)

Not currently recruiting at 13 trial locations
BG
NR
Overseen ByNicholas Rudzianski
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Iowa
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how different treatments for neuroendocrine tumors (NETs) affect people's lives. Researchers compare various therapies, such as biologic therapy and chemotherapy, to identify the best ways to reduce side effects and enhance treatment effectiveness. Participants will share their experiences through surveys about their quality of life and treatment choices. This trial suits those diagnosed with gastrointestinal or lung NETs from 2018 to 2024. As a Phase 2 trial, the research measures treatment effectiveness in an initial, smaller group, allowing participants to contribute to early-stage treatment evaluation.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on patient-reported outcomes for neuroendocrine tumors, which is a fresh approach compared to traditional clinical measures. Unlike standard treatments that primarily focus on tumor shrinkage or biochemical markers, this trial seeks to understand the real-world impact of treatments on patients' quality of life. By prioritizing the patients' perspectives, researchers hope to gather insights that could lead to more personalized and effective care strategies for those living with neuroendocrine tumors. This shift in focus could potentially reshape how treatments are evaluated and improve the overall treatment experience for patients.

Who Is on the Research Team?

MO

Michael O'Rorke, PhD

Principal Investigator

University of Iowa

Are You a Good Fit for This Trial?

Inclusion Criteria

(b) patient self-attestation of their diagnosis.
(2) Diagnosis of GEP-NET or lung NET between 1/1/2019 and 12/31/2023, as evidenced by
(a) medical record information on diagnoses and/or medications and/or treatments and/or test results and/or clinical notes and/or procedures and/or encounters and/or tumor characteristics,

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive various therapeutic options including biologic therapy, liver directed therapy, radiotherapy, and chemotherapy

18 months
4 surveys (online or paper)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with medical record outcomes followed up to 60 months

60 months

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Iowa

Lead Sponsor

Trials
486
Recruited
934,000+

University of Pittsburgh Medical Center

Collaborator

Trials
78
Recruited
77,600+

Neuroendocrine Tumor Research Foundation

Collaborator

Trials
2
Recruited
2,600+

University of Texas Southwestern Medical Center

Collaborator

Trials
1,102
Recruited
1,077,000+

Northern California CarciNET Community

Collaborator

Trials
1
Recruited
2,500+

University of Utah

Collaborator

Trials
1,169
Recruited
1,623,000+

Medical University of South Carolina

Collaborator

Trials
994
Recruited
7,408,000+

Healing NET Foundation

Collaborator

Trials
1
Recruited
2,500+

Vanderbilt University Medical Center

Collaborator

Trials
922
Recruited
939,000+

Allina Health System

Collaborator

Trials
60
Recruited
1,178,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security